Search

Displaying results 8721 - 8730 of 9686 in total
  1. Drug

    PRGN-3006

    go.drugbank.com/drugs/DB17229
    Investigational

    PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface

    Synonyms: Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface
  2. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  3. Drug

    GVAX

    go.drugbank.com/drugs/DB17276
    Investigational

    GVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine.

  4. Drug

    Dasiprotimut-T

    go.drugbank.com/drugs/DB17287
    Experimental

    Dasiprotimut-T is a personalized therapeutic vaccine against B-cell lymphomas.[A254701] It has been investigated in clinical trials.

  5. Drug

    LV305

    go.drugbank.com/drugs/DB17288
    Investigational

    LV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with [G305].[L47346]

  6. Drug

    Leuvectin

    go.drugbank.com/drugs/DB17303
    Investigational

    Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE

  7. Drug

    CAR BCMA-CS1

    go.drugbank.com/drugs/DB17313
    Experimental

    CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.

  8. Drug

    TPIV 200

    go.drugbank.com/drugs/DB17318
    Investigational

    TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).

  9. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

  10. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

    Synonyms: A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING